Lab Sciences
Top stories summarized by our editors
1/16/2020

ViiV Healthcare's combo HIV drug Dovato, or dolutegravir plus lamivudine, gained the approval of Japan's Ministry of Health, Labor and Welfare based on data from two international trials participated in by 1,400 HIV-infected people. Dovato is a single-pill antiretroviral therapy taken once a day approved to treat HIV-1 infection in adults and adolescents above the age of 12 who weigh at least 40 kilograms.

Full Story:
PharmaPhorum (UK)
More Summaries:
ViiV Healthcare, ViiV
1/16/2020

Andelyn Biosciences is a biotech spun off by Nationwide Children's Hospital that will focus on manufacturing gene therapy components for use in clinical trials. "Commercial-scale manufacturing represents one of the next significant barriers to the continued development of the field," said Dennis Durbin, chief scientific officer of Nationwide's Abigail Wexner Research Institute.

Full Story:
BioPharma Dive
1/16/2020

Details from research published in the journal Nature suggest that finding B cells within a tumor's tertiary lymphoid structures could help predict a patient's potential response to immune checkpoint blockers.

Full Story:
News Medical
1/15/2020

Biocept announced the validation of its Target Selector liquid biopsy assays to determine the presence of biomarkers and circulating tumor cells in the cerebrospinal fluid of breast and lung cancer patients suspected of having central nervous system or brain metastases.

Full Story:
Seeking Alpha
1/15/2020

Astellas and Adaptimmune have partnered to develop T-cell receptor and allogeneic chimeric antigen receptor T-cell therapies. Adaptimmune will be paid $50 million plus $7.5 million per year to fund the research, in addition to potential milestone payments.

Full Story:
FierceBiotech
1/14/2020

The European Medicines Agency has agreed to allow Emergent BioSolutions to move toward a Phase III trial of its chikungunya virus vaccine candidate. A Phase II trial of the National Institute of Allergy and Infectious Diseases-licensed vaccine is being conducted in the US.

Full Story:
Seeking Alpha
1/14/2020

Chimeric antigen receptor-T cell therapy continues to expand and show potential in changing the clinical course of diseases, writes pathology and immunology assistant professor Suzanne Thibodeaux of Washington University in St. Louis School of Medicine. Thibodeaux outlines the steps clinical laboratorians should consider to improve clinical management while ensuring patients receive optimal care throughout the process of CAR-T cell therapy.

More Summaries:
Washington University
1/14/2020

The FDA has granted breakthrough device designation to KDx Diagnostics' URO17 test that detects recurrent bladder cancer from urine samples. An initial study showed that the non-invasive test yielded 100% sensitivity and 96% specificity in identifying recurrent bladder cancer.

Full Story:
PharmaBiz (India)
More Summaries:
KDx Diagnostics
1/13/2020

The CDC estimates there have been 9.7 million flu cases, 87,000 flu-related hospitalizations and 4,800 flu-related fatalities, including 32 pediatric deaths, so far this season. As of the week ending Jan. 4, high flu activity was reported in 33 states, while widespread flu activity was reported in 46 states.

1/13/2020

Researchers found that bacteria that had developed resistance to one antibiotic were less susceptible to other antibiotics, suggesting that combining several antibiotics could result in increased resistance, according to a study in the journal Science. The findings were based on lab studies of bacteria taken from two patients with persistent blood infections.